Oxford BioDynamics (LON:OBD) Posts Quarterly Earnings Results

Oxford BioDynamics (LON:OBD) released its quarterly earnings data on Tuesday. The biotechnology company reported GBX (0.10) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative net margin of 1,018.54% and a negative return on equity of 316.67%.

Oxford BioDynamics Stock Performance

LON:OBD opened at GBX 0.09 on Thursday. The company has a market capitalization of £3.86 million, a price-to-earnings ratio of -0.11 and a beta of 0.42. Oxford BioDynamics has a 1-year low of GBX 0.08 and a 1-year high of GBX 0.78. The business has a 50 day moving average of GBX 0.18 and a 200 day moving average of GBX 0.23. The company has a debt-to-equity ratio of 457.97, a current ratio of 0.88 and a quick ratio of 2.80.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.